Beigene Ltd
SSE:688235
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
102.01
191
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Beigene Ltd
Beigene Ltd
Net Income (Common)
Beigene Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Beigene Ltd
SSE:688235
|
Net Income (Common)
-¥6.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Tanvex BioPharma Inc
TWSE:6541
|
Net Income (Common)
-NT$1.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Polaris Group
TWSE:6550
|
Net Income (Common)
-NT$1.6B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
Glance View
BeiGene Ltd., a global powerhouse in biopharmaceutical innovation, traces its journey back to its roots in Beijing, having established itself with a clear vision—to address the vast unmet needs in cancer treatment. Co-founded by John V. Oyler in 2010, the company set out on a mission to develop effective and accessible therapies for cancer patients worldwide. Operating at the intersection of cutting-edge science and global entrepreneurship, BeiGene built its reputation by investing heavily in research and development. The crux of its model hinges on leveraging both in-house capabilities and strategic collaborations. This has allowed it to expedite the development of a rich pipeline of oncology therapies, with a focus on small molecule drugs and monoclonal antibodies, navigating the complex world of biotechnology to bring pioneering solutions to market. Central to BeiGene's financial engine is its adeptness at creating a portfolio of marketable cancer therapies, primarily through licensing agreements and strategic partnerships. The company's business model thrives on advancements like Brukinsa, a treatment for certain types of lymphoma, which has seen significant regulatory approvals worldwide. Partnerships with pharmaceutical giants, such as Amgen, have amplified its global reach, enabling it to widen its distribution network beyond China to North America and Europe. By embedding itself into various markets and healthcare systems, BeiGene captures revenue through product sales, milestone payments, royalties, and collaboration fees. This multifaceted approach not only spearheads its growth trajectory but also solidifies its reputation as a company committed to combating cancer on a global scale, driven by innovation and an unwavering dedication to its mission.
See Also
What is Beigene Ltd's Net Income (Common)?
Net Income (Common)
-6.7B
CNY
Based on the financial report for Dec 31, 2023, Beigene Ltd's Net Income (Common) amounts to -6.7B CNY.
What is Beigene Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-7%
Over the last year, the Net Income (Common) growth was 51%. The average annual Net Income (Common) growth rates for Beigene Ltd have been 16% over the past three years , -7% over the past five years .
You don't have any saved screeners yet